Circulating Soluble CD163: A Potential Predictor for the Functional Outcome of Acute Ischemic Stroke

Houchao Sun1,2,3, Xiaogang Zhang2,3,4, Jingxi Ma2,3, Zhao Liu2,3, Yunwen Qi2,3, Li Fang2,3, Yongling Zheng2,3 and Zhiyou Cai1,2,3*

1Department of Neurology, Chongqing Medical University, Chongqing, China, 2Department of Neurology, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China, 3Chongqing Key Laboratory of Neurodegenerative Diseases, Chongqing, China, 4Chongqing Key Laboratory of Neurology, Department of Neurology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Background: CD163 is a transmembrane glycoprotein receptor expressed on innate immune cells that sheds from the cell membrane and circulates as a soluble form (sCD163). This study aimed to investigate the circulating levels and clinical relevance of soluble CD163 (sCD163) in acute ischemic stroke (AIS).

Methods: This study recruited 300 patients with AIS and 78 healthy controls. The patients were followed up for 1 month to observe the functional outcomes. The neurological functions of the patients were assessed using the NIH Stroke Scale (NIHSS) and the modified Rankin Scale (mRS). The plasma concentrations of sCD163 at the baseline (patient admission) were determined by ELISA.

Results: We found that patients with AIS had significantly higher plasma sCD163 concentrations than the healthy control. Patients with high sCD163 concentrations had better functional outcomes than patients with low sCD163 concentrations. The plasma sCD163 concentrations were positively associated with the NIHSS scores and infarction volume at the baseline. The plasma sCD163 was positively associated with the improvement of the NIHSS scores but was negatively associated with the risk of poor functional outcomes during follow-up.

Conclusions: These findings indicate that circulating sCD163 is a potential biomarker that is associated with disease severity and the functional outcome of AIS.

Keywords: acute ischemic stroke, biomarker, soluble CD163, short-term, functional outcome

INTRODUCTION

Stroke is one of the leading causes of death and disability worldwide (1). Biomarkers with the potential in identifying patients with a risk of having poor clinical outcomes are critical for aggressive monitoring and therapeutic interventions in these subjects. A panel of blood-based biomarkers is suggested to be predictive for the severity and prognosis of acute ischemic stroke (AIS) (2, 3).

The plasma membrane glycoprotein receptor CD163 is a member of the scavenger receptor cysteine-rich (SRCR) superfamily class B that is mostly expressed on monocytes and macrophages. CD163 could shed from cell membranes to
release soluble CD163 (sCD163) upon stimulation by inflammatory stimuli (4). sCD163 has been suggested to be biomarkers of many diseases, such as infectious diseases (5), tumors (6), and autoimmune diseases (7). sCD163 is increased in patients with intracranial hemorrhage and is associated with the improvement of neurological functions by promoting hematoma absorption (8). AIS involves local immune responses that encompass brain resident microglia and monocytes infiltrating from the circulation (9). The CD163 induced anti-inflammatory effects of monocyctic cells are suggested to be involved in the pathogenesis of AIS (10). Animal studies have demonstrated that CD163 is upregulated following AIS (11). However, the changes of circulating sCD163 in patients with AIS are unknown. Therefore, this study aims to investigate the levels and clinical relevance of sCD163 in patients with AIS.

MATERIALS AND METHODS

Subjects
Patients with their first AIS (to exclude the effects of previous AIS events on circulating sCD163 concentrations) who visited the Department of Neurology, Chongqing General Hospital, University of Chinese Academy of Sciences during January 1, 2019, and January 31, 2020, were screened. The inclusion criteria included: (1) patients with newly onset AIS; (2) who visited the hospital within 24 h after symptom onset; (3) who are willing to participate. Seventy-eight age and sex-matched healthy subjects were recruited as controls from the healthy examination center of the same hospital. Subjects with diseases that might influence the circulating sCD163 levels were excluded from participation. Therefore, subjects were excluded if they have: (1) co-existing infections; (2) any types of tumors; (3) any types of autoimmune diseases; (4) other conditions that may influence the blood sCD163 levels, such as cirrhosis and severe inflammatory diseases; (5) declined to participate in this study. The patients were screened for eligibility for participation right after admission. However, although diabetes mellitus may contribute to the alteration of sCD163 (12), patients with diabetes mellitus were not excluded as it is a significant risk factor of AIS. Finally, 300 patients and 78 healthy controls were recruited in this study after excluding the subjects who failed for inclusion. Written informed consents for participation in this study and blood sampling were obtained from the subjects or their legal relatives. This study conformed with the principles of the Declaration of Helsinki and was approved by the investigational review board of the Chongqing General Hospital, University of Chinese Academy of Sciences.

Clinical Evaluation
At baseline (time of patient admission), the demographic information such as age, sex, and body mass index (BMI), pre-stroke medical history including oral antiplatelet or anticoagulants drug use, comorbidities including hypertension, diabetes mellitus, hypercholesteremia, and atrial fibrillation were collected and assessed right after admission. AIS was diagnosed according to the WHO Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (WHO-MONICA) criteria with verification by MRI performed within 12 h after admission. The neurological deficits were examined with the National Institutes of Health Stroke Scale (NIHSS) upon admission (13), performed by a certified stroke neurologist. The AIS subtype was determined with the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (14).

Patients’ Follow-Up
The patients were followed up for 1 month since admission for the observation of functional outcomes. The primary endpoint was neurological functions 1 month since admission. The functional outcomes were assessed using NIHSS and the modified Rankin Scale (mRS) (15), which were blinded to the plasma sCD163 concentrations.

Blood Sampling and Measurement of CD163
Blood sampling was conducted right after patient admission before they receive any medical interventions. The blood was centrifuged right after collection at 20°C, spun at 2,000 g for 10 min, and stored at −80°C for biochemical analysis. The plasma sCD163 levels were determined using a human CD163 ELISA kit (Abcam, USA) according to the manufacturer instructions. To preserve the linearity of the assays, samples containing high concentrations of sCD163 were diluted with an appropriate amount of calibrator diluent. The minimum detectable dose of sCD163 was 1.377 ng/ml, which was significantly lower than the sCD163 concentrations of the subjects in this study. Each test was conducted in duplicates and the means were used for statistical analysis.

Statistical Analysis
If continuous variables were normally distributed, an independent t-test was used, and if not, a Mann-Whitney U-test was used. Two-sample tests of proportions were used to compare the proportions for the categorical variables. The comparisons of means among groups were conducted using one-way ANOVA and the comparisons of the rate of NIHSS change during the follow-up between groups were conducted using two-way ANOVA. Spearman correlation analyses were conducted to assess the association between plasma sCD163 concentrations and NIHSS or infarction volume. A linear regression model was utilized to investigate the association between the plasma sCD163 levels and functional improvement (as indicated by the change of NIHSS during follow-up). A logistical regression model was utilized to evaluate the risk factors of poor functional outcome (as indicated by mRS≥4) during follow-up. We first fitted univariate models with a single candidate variable at one time. The potential risk factors as determined by p < 0.05 were included in the final multivariate regression model. Statistical analyses were conducted using SPSS statistical package version 24 (IBM SPSS Statistics for Windows, Armonk, NY, USA).
RESULTS

Demographic Characteristics of Subjects

Three-hundred-nine patients with AIS and 99 healthy controls were screened for eligibility for participation in this study. Two-hundred-nine patients failed screening due to the following reasons: 176 patients declined to participate, 2 patients deceased during hospitalization, 11 patients had co-existing infections, 13 patients had previously diagnosed tumors, and 7 patients had autoimmune diseases. Twenty-one healthy controls declined to participate in this study. Finally, 300 AIS patients and 78 healthy controls participated in this study (Figure 1).

The patients were further divided into the high and low plasma sCD163 groups, respectively, according to their plasma sCD163 concentrations. The patients had significantly higher median BMI than the healthy controls. No significant differences in the mean age, percentages of males, frequencies of subjects with a history of smoking, antiplatelet drug use, antithrombotic drug use, a family history of stroke, hypertension, diabetes mellitus, hypercholesteremia, and atrial fibrillation between the patients and controls were observed. The high sCD163 group had a significantly higher proportion of males, a higher median diffusion-weighted imaging (DWI) hyperintensity volume, higher NIHSS scores at baseline, and higher frequencies of lacunar-type stroke than the low sCD163 group. However, there was no difference in the mean age, median BMI, frequency of smoking, antiplatelet drug use, antithrombotic drug use, family history of stroke, comorbidities including hypertension, diabetes mellitus, hypercholesteremia, and atrial fibrillation between the two groups. Besides, the median DWI hyperintensity volume, the median NIHSS and mRS scores at follow-up, frequencies of atherothrombotic, cardioembolic, and unknown type stroke, frequencies of hemorrhagic transformation, and recurrent AIS during follow-up were not significantly different between the high and low sCD163 groups (Table 1).

Plasma Concentrations and Clinical Relevance of sCD163 in AIS

We first compared the sCD163 concentrations between the patients with AIS and the control. We found that patients with AIS had significantly higher plasma sCD163 concentrations than the control (mean ± SD: 618.1 ± 292.0 ng/ml vs. 408.8 ± 157.5 ng/ml, p < 0.001) (Figure 2A). The high sCD163 group had better functional improvement as indicated by the change of NIHSS during follow-up than the low sCD163 group (p < 0.001) (Figure 2B). The plasma sCD163 concentrations were positively associated with the NIHSS at baseline (γ = 0.609, p < 0.001) and the DWI hyperintensity volume (γ = 0.509, p < 0.001) (Figures 2C,D). However, plasma sCD163 concentrations were not significantly associated with NIHSS at follow-up (γ = 0.049, p = 0.401) (Figure 2E). Patients with an mRS = 3 had significantly higher sCD163 concentrations than patients with an mRS = 1 (p < 0.001), 2 (p < 0.001), 4 (p < 0.001), and 5 (p < 0.001) (Figure 2F). Plasma sCD163 concentrations were positively associated with peripheral monocyte count, but no significance had been achieved (γ = 0.108, p = 0.062) (Figure 2G).

Factors Associated With Plasma sCD163 Levels

We utilized a linear regression model to investigate potential factors that were associated with plasma sCD163 levels. We found that hypercholesteremia and DWI hyperintensity volume were significantly associated with plasma sCD163 levels. These two factors along with diabetes mellitus, which is well-validated to be associated with sCD163 levels, were excluded from subsequent analysis (Table 2).
TABLE 1 | Demographic data of subjects.

| Variables                      | Control (n = 78) | Low sCD163 group (n = 150) | High sCD163 group (n = 150) | P-value Control vs. patients | P-value Low vs. High |
|--------------------------------|------------------|----------------------------|----------------------------|----------------------------|----------------------|
| Age, Mean (SD)                 | 62.86 (10.89)    | 64.83 (9.20)               | 66.16 (9.34)               | 0.082                      | 0.756                |
| Male, No. (%)                  | 48 (61.54)       | 95 (63.33)                 | 75 (50.00)                 | 0.520                      | 0.027^{b}            |
| BMI, Median (IQR)              | 23.85 (22.28, 25.33) | 24.68 (23.14, 25.76) | 24.19 (22.96, 25.37) | 0.029                      | 0.086                |
| Smoking history, No. (%)       | 7 (8.97)         | 11 (7.33)                  | 16 (10.67)                 | 0.437                      | 0.420^{b}            |
| Antiplatelet drug use, No. (%) | 9 (11.54)        | 21 (14.00)                 | 19 (12.67)                 | 0.850                      | 0.865^{b}            |
| Antithrombotic drug use, No. (%) | 4 (5.13)       | 13 (8.67)                  | 6 (4.00)                   | 1.000                      | 0.153^{b}            |
| Family history of stroke, No. (%) | 3 (3.85)      | 9 (6.00)                   | 9 (6.00)                   | 0.587                      | 1.000^{b}            |
| Comorbidities                  |                  |                            |                            |                            |                      |
| Hypertension, No. (%)          | 21 (26.92)       | 52 (34.67)                 | 51 (34.00)                 | 0.226                      | 1.000^{b}            |
| Diabetes Mellitus, No. (%)     | 13 (16.67)       | 26 (17.33)                 | 23 (15.33)                 | 1.000                      | 0.755^{b}            |
| Hypercholesteremia, No. (%)    | 6 (7.68)         | 9 (6.00)                   | 19 (12.67)                 | 0.825                      | 0.072^{b}            |
| Atrial fibrillation, No. (%)   | 7 (8.97)         | 13 (8.67)                  | 6 (4.00)                   | 0.451                      | 0.153^{b}            |
| DWI hyperintensity volume, ml (SD) | NA              | 24.56 (8.86)              | 32.36 (7.53)              | NA                        | 0.000^{a}            |
| NIHSS at baseline, Median (IQR) | NA              | 8 (3, 13)                  | 15 (11.75, 19)            | NA                        | 0.000^{c}            |
| NIHSS at follow-up, Median (IQR) | NA              | 4 (1, 9)                   | 6 (3, 7)                  | NA                        | 0.595^{c}            |

mRS at follow-up, Median (IQR) | Stroke etiology                  |                             |                             |                             |                      |
| Atherothrombotic, No. (%)      | NA                            | 122 (81.33)                 | 131 (87.33)                | NA                        | 0.204^{b}            |
| Cardioembolic, No. (%)         | NA                            | 13 (8.67)                   | 6 (4.00)                   | NA                        | 0.153^{b}            |
| Lacunar, No. (%)               | NA                            | 13 (8.67)                   | 4 (2.67)                   | NA                        | 0.043^{b}            |
| Unknown, No. (%)               | NA                            | 2 (1.33)                    | 9 (6.00)                   | NA                        | 0.061^{b}            |

Complication                      |                             |                             |                             |                             |                      |
| Hemorrhagic transformation, No. (%) | NA                          | 3 (2.00)                    | 7 (4.67)                   | NA                        | 0.335^{b}            |
| Recurrent AIS, No. (%)          | NA                            | 4 (2.67)                    | 1 (0.67)                   | NA                        | 0.371^{b}            |
| rtPA treatment, No. (%)         | NA                            | 13 (8.67)                   | 16 (10.67)                 | NA                        | 0.697^{b}            |
| mRS scores, Median (IQR)        | NA                            | 2 (0.4)                     | 3 (2.3)                    | NA                        | 0.641^{c}            |

IQR, Inter-Quartile Range; BMI, Body Mass Index; TICS, Telephone Interview of Cognitive Status 40; NIHSS, National Institutes of Health Stroke Scale; NA, not applicable.

Unpaired t-test; ^bPearson χ^2-test; ^cMann-Whitney U-test. Bold values represents statistically significant.

Association Between Plasma sCD163 Levels and Functional Improvement During Follow-Up

We first utilized a linear regression model to investigate the association between plasma sCD163 levels and functional improvement during follow-up as indicated by the decrease of NIHSS. Factors that are potentially associated with sCD163 levels were excluded from the model, including hypercholesteremia, DWI hyperintensity volume, and diabetes mellitus. Male sex and higher sCD163 concentrations were found to be positively associated with functional improvement during follow-up (Table 3).

Association Between Plasma sCD163 Concentrations and Poor Functional Outcome During Follow-Up

We next utilized a logistical regression model to investigate the association between plasma sCD163 concentrations and poor functional outcome during follow-up as indicated by mRS ≥ 4. In the univariate analyses, stroke type was found to be associated with poor functional outcomes during follow-up. Higher sCD163 concentrations were found to be protective factors of poor functional outcome during follow-up, and these associations remained significant in the multivariate analyses (Table 4).

DISCUSSION

In this study, we investigated the levels and clinical relevance of sCD163 in AIS. We found that patients with AIS had increased circulating sCD163 concentrations. sCD163 concentrations were associated with the severity and prognosis of AIS. Specifically, sCD163 was positively associated with the improvement of neurological functions but negatively associated with the risk of poor prognosis in AIS during follow-up.

Previous studies suggest that the AIS-associated inflammatory component is partly driven by the myeloid immune compartment, including microglia, peripheral monocytes, and macrophages (16). Numerous studies identified alterations in immune biomarkers in the cerebral spinal fluid (CSF) and
Sun et al. CD163 in Acute Ischemic Stroke

FIGURE 2 | Plasma soluble CD163 (sCD163) is increased in patients with acute ischemic stroke (AIS) and associated with disease severity. (A) Plasma sCD163 concentrations in AIS patients and control. Independent sample t-test. (B) The trajectory of neurological function as indicated by the change of the National Institutes of Health Stroke Scale (NIHSS) during follow-up. Two-way ANOVA. (C) Association between plasma sCD163 concentrations and NIHSS at baseline. Spearman correlation analysis. (D) Association between plasma sCD163 concentrations and NIHSS at follow-up. Spearman correlation analysis. (E,F) Association between plasma sCD163 concentrations and diffusion-weighted imaging (DWI) hyperintensity volume. (G) Association between plasma sCD163 concentrations and circulating monocyte count. DWI, Diffusion-weighted imaging. Spearman correlation analysis.

blood that are associated with the severity and prognosis of AIS (17). However, few of these biomarkers are cell type-specific and thus provide limited information on cellular relevance in the pathogenesis of AIS. Here, we show that plasma sCD163, a monocyte/macrophage-specific biomarker, was increased in AIS, hence suggesting increasing monocytic activation after AIS. sCD163 was associated with the disease severity as reflected by the NIHSS and infarction volume at the baseline. In previous studies, sCD163 is suggested to be increased in a panel of neurological diseases, such as intracranial hemorrhage (18), Parkinson's disease (19), Alzheimer's disease (20), and multiple sclerosis (21). These diseases without exception involve monocytic activation. Therefore, we suppose that the increase in sCD163 levels after AIS is indicative of monocytic activation, which is a well-documented phenomenon in AIS (22). This notion is further supported by our findings that plasma sCD163 concentrations were associated with peripheral monocyte count, although no significance had been achieved. Monocyte activation may attenuate with the diminishment of the post-AIS inflammation and the recovery of the disease (10), which is supported by the loss of association between plasma sCD163 concentrations and NIHSS at follow-up when neurological functions had been significantly improved.

Ischemic stroke causes local inflammation, which involves both the activation of resident microglia and infiltrating of
TABLE 2 | A linear regression model to investigate potential factors associated with plasma sCD163 levels.

| Variables                  | β unadjusted | S.E. | β adjusted | P-value |
|----------------------------|--------------|------|------------|---------|
| Constant                   | 264.512      | 283.288 |          | 0.351  |
| Age                        | −0.241       | 1.611 | −0.008    | 0.881  |
| Male                       | −56.423      | 33.021 | −0.096    | 0.089  |
| BMI                        | −2.757       | 10.833 | −0.014    | 0.799  |
| Hypertension               | 5.681        | 32.151 | 0.009     | 0.860  |
| Diabetes mellitus          | −86.343      | 40.596 | −0.084    | 0.103  |
| Hypercholesteremia         | 116.374      | 52.105 | 0.116     | 0.026  |
| Smoking history            | 19.139       | 58.664 | 0.019     | 0.744  |
| Family history of stroke   | 37.071       | 70.546 | 0.030     | 0.600  |
| Stroke type                | 19.856       | 21.462 | 0.050     | 0.356  |
| DWI hyperintensity Volume  | 15.328       | 1.709 | 0.477     | 0.000  |
| Antiplatelet drug use       | 43.171       | 44.491 | 0.050     | 0.333  |
| Antithrombotic drug use     | −81.982      | 63.849 | −0.068    | 0.200  |

Dependent variable: sCD163 concentrations. Bold values represent statistically significant.

TABLE 3 | A linear regression model to evaluate the association between plasma sCD163 levels and functional improvement during follow-up.

| Variables                  | β unadjusted | S.E. | β adjusted | P-value |
|----------------------------|--------------|------|------------|---------|
| Constant                   | 2.177        | 3.616 | 0.548      |         |
| Age                        | −0.015       | 0.021 | −0.029     | 0.457  |
| Male                       | −1.885       | 0.430 | −0.186     | 0.000  |
| BMI                        | −0.039       | 0.141 | −0.012     | 0.784  |
| Hypertension               | 0.152        | 0.417 | 0.014      | 0.717  |
| Smoking history            | −0.654       | 0.758 | −0.037     | 0.389  |
| Family history of stroke   | 0.001        | 0.917 | 0.000      | 0.999  |
| Stroke type                | 0.018        | 0.274 | 0.003      | 0.947  |
| Antiplatelet drug use       | 0.491        | 0.571 | 0.033      | 0.391  |
| Antithrombotic drug use     | −0.432       | 0.829 | −0.021     | 0.603  |
| sCD163 concentrations       | 0.012        | 0.001 | 0.686      | 0.000  |

Dependent variable: Functional improvement as indicated by the change of NIHSS during follow-up (NIHSS at baseline—NIHSS at follow-up). Factors that are potentially associated with sCD163 levels were excluded from the model. Bold values represent statistically significant.

TABLE 4 | A logistic regression model to evaluate risk factors of poor functional outcome during follow-up.

| Variables                  | Univariable ORs (95%CI) | P value | Multivariable ORs (95%CI) | P-value |
|----------------------------|-------------------------|---------|---------------------------|---------|
| Age                        | 0.987 (0.957, 1.018)    | 0.394   |                           |         |
| Sex, male vs. female       | 1.413 (0.789, 2.533)    | 0.245   |                           |         |
| BMI                        | 1.044 (0.865, 1.260)    | 0.656   |                           |         |
| Hypertension, yes vs. no   | 0.782 (0.424, 1.442)    | 0.430   |                           |         |
| Diabetes mellitus, yes vs. no | 0.509 (0.206, 1.259)   | 0.144   |                           |         |
| Hypercholesteremia, yes vs. no | 0.858 (0.312, 2.358)  | 0.766   |                           |         |
| Smoking history, yes vs. no | 0.737 (0.208, 2.616)   | 0.637   |                           |         |
| Family history of stroke, yes vs. no | 1.159 (0.446, 3.011) | 0.762   |                           |         |
| Stroke type                | 0.456 (0.225, 0.925)    | 0.030   | 0.392 (0.184, 0.835)      | 0.015   |
| Antiplatelet drug use, yes vs. no | 0.532 (0.199, 1.423)  | 0.209   |                           |         |
| Antithrombotic drug use, yes vs. no | 0.737 (0.208, 2.616) | 0.637   |                           |         |
| sCD163 concentrations, high vs. low | 0.351 (0.191, 0.644) | 0.001   | 0.998 (0.997, 0.999)      | 0.000   |

Dependent variable: Poor outcome as indicated by mRS = 4 or 5 at follow-up. Factors that are potentially associated with sCD163 levels were excluded from the model. Bold values represent statistically significant.
relationship between functional outcomes following AIS and increased plasma levels of CD163, which might be a true phenomenon but also unrelated to disease severity and functional outcomes. This study lacks experimental evidence to support the interpretations.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
This study was approved by the investigational review board of the Chongqing General Hospital, University of Chinese Academy of Sciences. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. GBD 2013 Mortality and Causes of Death Collaborators. Causes of Death, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. (2015) 385:117-71. doi: 10.1016/S0140-6736(14)61682-2
2. Stanne TM, Aberg ND, Nilsson S, Jood K, Blomstrand C, Andreasson U, et al. Low circulating acute brain-derived neurotrophic factor levels are associated with poor long-term functional outcome after ischemic stroke. Stroke. (2016) 47:1943–5. doi: 10.1161/STROKEAHA.115.012383
3. Baerts L, Brouns R, Kehoe K, Verkerk B, Engelborghs S, De Deyn PP, et al. Acute ischemic stroke severity, progression, and outcome relate to changes in dipeptidyl peptidase iv and fibroblast activation protein activity. Transl Stroke Res. (2017) 8:157–64. doi: 10.1007/s12975-016-0493-3
4. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, therapeutic aspects. Antioxid Redox Signal. (2013) 18:2352–63. doi: 10.1089/ars.2012.4834
5. Zingaropoli MA, Nijhawan P, Carraro A, Pasculi P, Zuccala P, Perri V, et al. Increased sCD163 and sCD14 plasmatic levels and depletion of peripheral blood pro-inflammatory monocytes, myeloid and plasmacytoid dendritic cells in patients with severe COVID-19 pneumonia. Front Immunol. (2021) 12:627548. doi: 10.3389/fimmu.2021.627548
6. Vajavaara H, Ekeblad F, Holte H, Jorgensen J, Levienon SK, Berglund M, et al. Prognostic impact of soluble CD163 in patients with diffuse large B cell lymphoma. Haematologica. (2021) 106:2502–6. doi: 10.3324/haematol.2020.278182
7. Zhang T, Li H, Vanarsa K, Gidley G, Mok CC, Tatarishvili R, Jenkins DJA, et al. The association of soluble CD163, a novel biomarker of macrophage activation, with type 2 diabetes mellitus and its underlying physiological disorders: a systematic review. Obes Rev. (2021) 22:e13257. doi: 10.1111/obr.13257
8. Xie Y, Nie D, Wang LJ, Qiu HC, Ma L, Dong MX, et al. Microglial polarization: novel therapeutic strategy against ischemic stroke. Aging Dis. (2021) 12:466–79. doi: 10.14336/AD.2020.0701
9. Cavrak ME, Hass R, Stephens RJ, Adcock A, Petrone AB. Leukocyte biomarkers for the differential diagnosis of mild acute ischemic stroke, transient ischemic attack, stroke mimic. Cereus. (2021) 13:e13383. doi: 10.7759/cureus.13383
10. Garten T, Keep RF, Hua Y, Xi G. CD163, a hemoglobin/haptoglobin scavenger receptor, after intracerebral hemorrhage: functions in microglia/macrophages versus neurons. Transl Stroke Res. (2017) 8:612–616. doi: 10.1007/s12975-017-0535-5
11. Farmen K, Nissen SK, Stokholm MG, Iranzo A, Ostergaard K, Serradell M, et al. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proc Natl Acad Sci USA. (2021) 118:2020858118. doi: 10.1073/pnas.2020858118
12. Swanson MEV, Scotter EL, Smyth LCD, Murray HC, Ryan B, Turner C, et al. Identification of a dysfunctional microglial population in human Alzheimer’s disease cortex using novel single-cell histology image analysis. Acta Neuropathol Commun. (2020) 8:170. doi: 10.1186/s40478-020-01047-9
13. De Fino C, Lucchini M, Lucchetti D, Nociti V, Losavio FA, Bianco A, et al. The predictive value of CSF multiple assay in multiple sclerosis: a single center experience. Mult Scler Relat Disord. (2019) 35:176–81. doi: 10.1016/j.msard.2019.07.030
14. Deng W, Mandeville E, Terasaki Y, Li W, Holder J, Chuang AT, et al. Transcripomc characterization of microglia activation in a rat model of ischemic stroke. J Cereb Blood Flow Metab. (2020) 40:834–48. doi: 10.1177/0271678X209932870

AUTHOR CONTRIBUTIONS

ZC and HS designed the study and drafted the manuscript. HS, XZ, JM, and ZL collected the samples and analyzed the data. YQ and LF supervised the project. YZ and LF were responsible for the clinical assessment of subjects. All authors contributed to the article and approved the submitted version.

FUNDING
The work was supported by the Science and Technology Committee of Yuzhong District of Chongqing (20180142), Natural Science Foundation of Chongqing (cstc2020jcyj-msxmX0058), Chongqing General Hospital (2019ZDMX03), and Chongqing Municipal Health Commission (2020MXXM106).

CD163 directly links innate immune system activation and adaptive immune system suppression following ischemic stroke. Sci Rep. (2017) 7:13940. doi: 10.1038/s41598-017-13291-6

CD163 in Acute Ischemic Stroke

Sun et al.

December 2021 | Volume 12 | Article 740420

Frontiers in Neurology | www.frontiersin.org
23. Rajan WD, Wojtas B, Giełniowski B, Miro-Mur F, Pedragosa J, Zawadzka M, et al. Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans. *Neurobiol Dis.* (2020) 137:104722. doi: 10.1016/j.nbd.2019.104722

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Sun, Zhang, Ma, Liu, Qi, Fang, Zheng and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*